Not available
Quote | DURECT Corporation (NASDAQ:DRRX)
Last: | $1.28 |
---|---|
Change Percent: | 0.0% |
Open: | $1.355 |
Close: | $1.28 |
High: | $1.36 |
Low: | $1.28 |
Volume: | 24,691 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | DURECT Corporation (NASDAQ:DRRX)
2024-05-21 10:10:08 ET More on DURECT DURECT Corporation (DRRX) Q1 2024 Earnings Call Transcript DURECT Corporation (DRRX) Q4 2023 Earnings Call Transcript DURECT Q1 2024 Earnings Preview DURECT and Charles River enter agreement for alzet in U.S., Canada ...
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis PR Newswire DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif. , May ...
Message Board Posts | DURECT Corporation (NASDAQ:DRRX)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $DRRX News Article - Durect Corp. (NASDAQ: DRRX) Making Surprising Moves in Monday Sess | whytestocks | investorshangout | 04/10/2023 5:05:48 PM |
100% agree. This will be a total loss | Distantpulse | investorshub | 12/07/2022 2:09:06 PM |
There is really nothing positive about a R/S | Foxwoods Man | investorshub | 12/06/2022 7:59:30 PM |
1/10 RS. 100% loss incoming. Smfh! | Distantpulse | investorshub | 12/06/2022 1:59:07 PM |
Been not liking this company since I was | Jimmy Joe | investorshub | 10/25/2022 8:45:12 PM |
News, Short Squeeze, Breakout and More Instantly...
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis PR Newswire DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif. , May ...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 171.6% to $0.1657 on volume of 180,907,472 shares AMC Entertainment Holdings Inc. Class A (AMC) rose 84.4% to $9.57 on volume of 174,658,682 shares Plug Power Inc. (PLUG) rose 45.9%...
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update PR Newswire - FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Ea...